Inverted U-shaped correlation between serum low-density lipoprotein cholesterol levels and cognitive functions of patients with type 2 diabetes mellitus

Haoqiang Zhang1,2, Wenwen Zhu1,2, Tong Niu1,2, Zheng Wang1,2, Ke An1,2, Wuyou Cao1,2, Jijing Shi1,2 and Shaohua Wang1,2*

Abstract

Background: Low-density lipoprotein cholesterol (LDL-C) metabolic disorder is common in individuals with diabetes. The role of LDL-C in mild cognitive impairment (MCI) remains to be explored. We aim to investigate the associations between LDL-C at different levels and details of cognition decline in patients with type 2 diabetes mellitus (T2DM).

Methods: Patients with T2DM (n = 497) were recruited. Clinical parameters and neuropsychological tests were compared between patients with MCI and controls. Goodness of fit was assessed to determine the linear or U-shaped relationship between LDL-C and cognitive function. The cut-off point of LDL-C was calculated. Correlation and regression were carried out to explore the relationship between cognitive dysfunction and LDL-C levels above and below the cut-off point.

Results: Although no significant difference in LDL-C levels was detected in 235 patients with MCI, compared with 262 patients without MCI, inverted-U-shaped association was determined between LDL-C and Montreal Cognitive Assessment (MoCA). The cut-off point of LDL-C is 2.686 mmol/l. LDL-C (>2.686 mmol/l) is positively related to Trail Making Test B (TMTB) indicating executive function. LDL-C (<2.686 mmol/l) is positively associated with Clock Drawing Test (CDT) reflecting visual space function in patients with T2DM.

Conclusion: Inverted U-shaped correlation was found between serum LDL-C and cognitive function in patients with T2DM. Despite that the mechanisms of different LDL-C levels involved in special cognitive dysfunctions remain incompletely clarified, excessive LDL-C damages executive function, while the deficient LDL-C impairs visual space function.

Trial registration: ChiCTR-OCC-15006060.

Keywords: Cholesterol, Low-density lipoprotein cholesterol, Lipids disorder, Type 2 diabetes mellitus, Cognitive function, Mild cognitive impairment
Background
Cholesterol in brain accounts for more than 20% of total cholesterol in human body [1]. Cholesterol plays a necessary role in the formation and maintenance of synapses [2]. Increase in age could significantly reduce the synthesis of cholesterol in astrocytes, which may lead to the loss of synapses [3]. In patients with Alzheimer’s disease (AD), the levels of enzymes associated with cholesterol synthesis in the brain decreased significantly, and the process of cholesterol synthesis changed [4]. Interestingly, insulin-deficient diabetic mice exhibited reduction in brain cholesterol synthesis and cognitive decline. Additionally, neurons may be protected by increased levels of cholesterol in the medium from cholesterol deficiency [5]. However, rons may be protected by increased levels of cholesterol in deficient diabetic mice exhibited reduction in brain cholesterol synthesis changed [4]. Interestingly, insulin-

Methods

Subjects and groups
A total of 497 patients aged 40–80 years (235 with MCI and 262 without MCI) were recruited between August 2013 and December 2019. The inclusion criteria were as follows: 1) all patients were Han Chinese (right-handed) and had education level of at least 6 years; and 2) the duration of T2DM was more than 3 years. The exclusion criteria were as follows: 1) acute diabetic complications; 2) acute cardiovascular or cerebrovascular diseases; 3) history of brain diseases; 4) abuse of alcohol or drug (in near 2 months); 5) thyroid dysfunction; 6) other illnesses, such as serious infection or surgery, cancer, or anemia (in near 6 months), that influence (or potentially influence) cognitive function, neuropsychological test, or measurement of blood samples; 7) visual or hearing loss; and 8) severe cognitive decline (out of the range of MCI). All individuals with diabetes had disease duration of more than 3 years. MCI was diagnosed by the criteria from the MCI Working Group of the European Consortium for Alzheimer’s Disease [29].

Clinical data
Data on age, sex, and education level as well as durations of T2DM and high blood pressure (HBP) were collected. Smoking history data were also gathered. When the patients obtained medical care in Zhongda Hospital, the levels of glycosylated hemoglobin (HbA1c), triglyceride (TG), total cholesterol (TC), LDL-C and high-density lipoprotein (HDL-C) were measured in blood samples by the Laboratory Center of our institution. Body mass indices (BMI) were calculated by height and body weight. The Laboratory Center of our institution implemented quality control standards according to the Chinese Laboratory Quality Control.

Neuropsychological tests
MoCA scores were used to assess global cognitive abilities. One score was added if the years of education were less than 12. Digit Span Test (DST), Verbal Fluency Test (VFT) and TMTB were conducted to evaluate patients’ executive functions. CDT was used to analyze for visual space function. Trail Making Test-A (TMTA) test was
performed to assess information processing speed function. The enrolled patients with T2DM were divided into two groups: MCI group (< 26) and Non-MCI group (≥ 26). MoCA score was calculated according to a previously reported method [30]. Additional information can be found at the website (https://www.mocatest.org/). CDT was included in the performance of MoCA. DST [31] and VFT [32] as well as TMTA and TMTB [33] were performed according to previous studies.

Statistical analysis
Statistical analyses were conducted by SPSS 20.0. Student’s t test, nonparametric Mann-Whitney U and Chi-squared test were performed for normally distributed, asymmetrically distributed, and binary variables, respectively. Curve fitting and line fitting were conducted to detect the relationship between LDL-C (or TC) and MoCA by curve estimation. Cut-off point (\(= b/2a \)) was calculated for U-shaped curve (with a regression equation: \(Y = aX^2 + bX + c \)). Pearson or partial correlation analysis was conducted to observe the association between LDL-C (or TC) and MoCA without or with adjustment by age, gender, education and HBP duration respectively. Binary logistic regression was used to explore the independent risk factors of MCI. Multiple linear regression was employed to investigate variables influencing TMTB and CDT in different populations. \(P < 0.05\) was defined as statistical significance.

Results
Baseline data of patients with T2DM in MCI or non-MCI group
Although increased cholesterol is a common risk factor of AD and our previous study showed that poorly controlled LDL-C is related to executive function in diabetic patients [13], no significant difference in TC and LDL-C levels were found among T2DM patients with or without MCI \((P = 0.196 \text{ and } 0.475 \text{ respectively})\). Age, gender and education levels varied among the patients in the two groups (All \(P < 0.001\)). Interestingly, the HBP

| Table 1 | Demographic, clinical and cognitive characteristics of T2DM patients with or without MCI |
|---------|---------------------------------------------------------------------|
|         | All individuals \((n = 497)\) | MCI \((n = 235)\) | Non-MCI \((n = 262)\) | \(P\) value |
| Age (year) | 60 (53–66) | 62 (56–68) | 58 (52–64) | \(<0.001^{*a}\) |
| Female (n, %) | 207 (41.6) | 117 (49.8) | 90 (34.4) | \(<0.001^{*a}\) |
| Education | 10 (9–12) | 9 (6–12) | 12 (9–12) | \(<0.001^{*a}\) |
| BMI (Kg/m\(^2\)) | 24.77 (22.77–27.04) | 24.57 (22.77–27.12) | 24.80 (22.75–26.86) | 0.869\(^b\) |
| DM Duration (year) | 10 (5–14) | 10 (5–15) | 10 (5–13) | 0.352\(^b\) |
| HBP Duration (year) | 3 (0–10) | 5 (0–15) | 1 (0–10) | 0.006\(^ab\) |
| Smoking (n, %) | 178 (35.8) | 79 (33.6) | 99 (37.8) | 0.333\(^c\) |
| Statins (n, %) | 265 (53.3) | 133 (56.6) | 132 (50.4) | 0.166\(^c\) |
| Other Antilipidemic Drugs (n, %) | 24 (4.8) | 15 (6.4) | 9 (3.4) | 0.126\(^c\) |
| HbA1c (%) | 8.60 (7.20–10.30) | 8.80 (7.50–10.50) | 8.40 (7.10–10.10) | 0.090\(^b\) |
| TG (mmol/l) | 1.48 (1.04–2.27) | 1.53 (1.00–2.38) | 1.48 (1.05–2.18) | 0.599\(^b\) |
| TC (mmol/l) | 4.60 ± 1.15 | 4.67 ± 1.24 | 4.54 ± 1.07 | 0.196\(^a\) |
| HDL-C (mmol/l) | 1.15 (1.00–1.34) | 1.16 (1.01–1.34) | 1.15 (0.98–1.32) | 0.300\(^b\) |
| LDL-C (mmol/l) | 2.82 (2.29–3.43) | 2.85 (2.23–3.63) | 2.81 (2.32–3.24) | 0.473\(^b\) |
| LDL-C/HDL-C | 2.43 (2.00–2.95) | 2.43 (1.98–3.03) | 2.42 (2.01–2.91) | 0.819\(^b\) |
| MoCA | 26 (23–27) | 22 (20–24) | 27 (26–28) | \(<0.001^{*a}\) |
| DST | 12 (10–13) | 11 (9–12) | 12 (11–14) | \(<0.001^{*a}\) |
| VFT | 16 (14–19) | 15 (13–18) | 18 (15–21) | \(<0.001^{*a}\) |
| CDT | 4 (3–4) | 3 (2–4) | 4 (3–4) | \(<0.001^{*a}\) |
| TMTA | 60 (49–83) | 71 (57–95) | 55 (45–67) | \(<0.001^{*a}\) |
| TMTB | 160 (123–205) | 185 (145–236) | 135 (106–178) | \(<0.001^{*a}\) |

Abbreviations: BMI Body mass index, DM Diabetes mellitus, HBP High blood pressure, FPG Fasting plasma glucose, TG Triglycerides, TC Total cholesterol, LDL-C Low density lipoprotein cholesterol, HDL-C High density lipoprotein cholesterol, MoCA Montreal Cognitive Assessment, DST Digit Span Test, VFT Verbal Fluency Test, CDT Clock Drawing Test, TMTA Trail Making Test-A, TMTB Trail Making Test-B, MCI Mild cognitive impairment.

The data are presented as n (%), or the median (inter-quartile range) unless otherwise specified.

- \(^{a}\)Student’s t test was employed for normally distributed variables.
- \(^{b}\)The Mann-Whitney U test was employed for asymmetrically distributed variables.
- \(^{c}\)The Chi-square test was employed for categorical variables.
- \(* P < 0.05\)
duration of patients with MCI was longer than that of patients without MCI \((P = 0.006)\). The HbA1c was higher in patients with MCI than in patients without MCI, but the difference was not significant \((P = 0.090)\). MoCA, DST, VFT, CDT, TMTA, and TMTB were significantly different between the two groups of patients \((All \ P < 0.001)\) (Table 1).

**Association between MoCA and TC (or LDL)**

Despite the lack of statistical significance in the difference of TC and LDL-C levels between patients with or without MCI, the relationship between MoCA and TC (or LDL-C) was analyzed. No correlation was found between TC (or LDL-C) and MoCA by Pearson association \((R = -0.056, \ P = 0.216 \text{ or } R = -0.058, \ P = 0.197)\). Although the association between TC and MoCA was not detected, the association between LDL-C levels and MoCA scores were observed by partial correlation adjusted by age, gender, education and HBP duration \((R = -0.087, \ P = 0.054 \text{ and } R = -0.099, \ P = 0.027)\) (Supplementary Table 1). Further binary logistic regression analysis indicated that LDL-C was not a risk factor of MCI in T2DM patients \((P = 0.062, \text{ OR } = 0.803)\) (Supplementary Table 2). Linear and U-shaped curve were compared to further explore the relationship between cholesterol and cognition decline. Interestingly, we detected an inverted-U-shaped cueve rather than a linear association between LDL-C and MoCA \((P = 0.044 \text{ vs } P = 0.196)\) (Fig. 1 and Supplementary Table 4). However, no significant linear association or U-shaped association was detected between TC and MoCA (all \(P > 0.05\)) (Supplementary Figure 1 and Supplementary Table 3). Additionally, the cut-off point of LDL-C was calculated to be 2.686 mmol/L.

**Association between cognitive function and LDL-C in different levels**

The associations between LDL-C and neuropsychological tests results above or below the cut-off point were analyzed by partial correlation adjusted by age, gender, education, HBP duration and HbA1c level to further explore the relationship between LDL-C and cognitive function. Although MoCA was not associated with LDL-C below 2.686 mmol/L, it was related to LDL-C above 2.686 mmol/L \((R = -0.143, \ P = 0.015)\). Moreover, LDL-C \((<2.686 \text{ mmol/L})\) was associated with CDT \((R = 0.151, \ P = 0.033)\), while LDL-C \((>2.686 \text{ mmol/L})\) was related to TMTB \((R = 0.180, \ P = 0.002)\) (Table 2).

**Binary logistic regression for risk factors of MCI**

Higher LDL-C level (above the cut-off point), not lower LDL-C level (below the cut-off point), was an independent risk factor of MCI in diabetic patients \((P = 0.012, \text{ OR } = 0.581)\) (Table 3).

---

**Fig. 1** Comparison of linear and U curve association between LDL-C and MoCA. Cut-off point of LDL-C: 2.686 mmol/L. Abbreviations: LDL-C, low density lipoprotein cholesterol; MoCA, Montreal Cognitive Assessment.
LDL-C levels were observed in diabetic patients with MCI, compared with those without MCI, no statistical significance was found. Despite that the association between LDL-C and MoCA was detected by partial correlation adjusted by age, gender, education and HBP duration, LDL-C was not an independent risk factor of MCI, which is assessed by binary logistic regression analysis in all patients.

These results confuse us. The relationship between cholesterol and cognitive function may not be a linear association because cholesterol is an essential element of the membrane of neurons and play a necessary role in the function of synapses. Extremely low cholesterol levels may damage cognitive function because increase in cholesterol could promote the survival of neurons. Moreover, high cholesterol levels (in the high normal range) may have a protective effect on cognitive function in old Chinese people [41]. The U-shaped relationship may exist between cholesterol levels and cognitive function. In other words, cholesterol deficiency destroys the structural integrity of neurons and affects their normal function. However, as a metabolic disorder, hypercholesterolemia also contributes to cognitive impairment by directly damaging the nervous system (for the modification of cholesterol including but not limited to oxidized cholesterol) or declining vascular cognition [42, 43].

To confirm the above hypothesis, we compared the linear and U-shaped relationship curves between cholesterol and cognitive function by goodness of fit. Although the U-shaped association between MoCA and TC was not confirmed, the U-shaped relationship between LDL-C and MoCA was found. Additionally, the cut-off point of LDL-C (2.686 mmol/L) was calculated. Partial correlation was conducted with adjustment for age, gender, education and HBP duration to assess the relationship between cognitive function (including details of cognitive function and global cognitive function) and LDL-C above/below the cut-off point. At LDL-C above 2.686 mmol/L, MoCA was associated with serum LDL-C. Moreover, increased LDL-C was found to be an independent risk factor of MCI in T2DM patients at this range by binary logistic regression. This finding is consistent with our previous work [13]. Xia et al.

Table 2: Association between cognitive function and LDL-C in different levels

| LDL-C ≤ 2.686 mmol/l | LDL-C > 2.686 mmol/l |
|----------------------|----------------------|
| R                    | P        | R        | P        |
| MoCA                 | 0.027    | 0.704    | -0.143   | 0.015*   |
| DST                  | 0.111    | 0.119    | -0.105   | 0.076    |
| VFT                  | -0.031   | 0.661    | -0.056   | 0.340    |
| CDT                  | 0.151    | 0.033*   | -0.065   | 0.270    |
| TMTA                 | 0.044    | 0.536    | -0.001   | 0.989    |
| TMTB                 | 0.002    | 0.981    | 0.180    | 0.002*   |

Abbreviations: LDL-C Low density lipoprotein cholesterol, MoCA Montreal Cognitive Assessment, DST Digit Span Test, VFT Verbal Fluency Test, CDT Clock Drawing Test, TMTA Trail Making Test-A, TMTB Trail Making Test-B

*P < 0.05

Multiple linear regression for the influence of LDL-C

Multiple linear regression was conducted to investigate the relationship between CDT and LDL-C below 2.686 mmol/l as well as TMTB and LDL-C above 2.686 mmol/l given that the partial correlation analysis showed the association between LDL-C and neuropsychological tests above or below 2.686 mmol/l. Interestingly, LDL-C is related to TMTB (P = 0.002, β = 19.393) (LDL-C>2.686 mmol/L), and associate with CDT (P = 0.033, β = -0.320) (LDL-C<2.686 mmol/L) as age, gender, education, HBP duration, HbA1c and LDL-C were entered as independent variables (Tables 4 and 5).

Discussion

Hyperglycemia is a well-recognized risk factor of cognition decline. Uncontrolled HbA1c levels were detected in our previous studies [34–36] and other works [37]. Although HbA1c levels were not significantly different, higher HbA1c levels were measured in patients with MCI than in patients without MCI in the present study.

Obesity commonly exists in patients with T2DM, who may easily suffer from hypercholesterolemia. Increasing number of studies have shown that hypercholesterolemia is a risk factor of cognition decline [38–40]. However, the results are conflicting. Although increased TC or LDL-C levels were observed in diabetic patients with MCI, compared with those without MCI, no statistical significance was found. Despite that the association between LDL-C and MoCA was detected by partial correlation adjusted by age, gender, education and HBP duration, LDL-C was not an independent risk factor of MCI, which is assessed by binary logistic regression analysis in all patients.

These results confuse us. The relationship between cholesterol and cognitive function may not be a linear association because cholesterol is an essential element of the membrane of neurons and play a necessary role in the function of synapses. Extremely low cholesterol levels may damage cognitive function because increase in cholesterol could promote the survival of neurons. Moreover, high cholesterol levels (in the high normal range) may have a protective effect on cognitive function in old Chinese people [41]. The U-shaped relationship may exist between cholesterol levels and cognitive function.

In other words, cholesterol deficiency destroys the structural integrity of neurons and affects their normal function. However, as a metabolic disorder, hypercholesterolemia also contributes to cognitive impairment by directly damaging the nervous system (for the modification of cholesterol including but not limited to oxidized cholesterol) or declining vascular cognition [42, 43].

To confirm the above hypothesis, we compared the linear and U-shaped relationship curves between cholesterol and cognitive function by goodness of fit. Although the U-shaped association between MoCA and TC was not confirmed, the U-shaped relationship between LDL-C and MoCA was found. Additionally, the cut-off point of LDL-C (2.686 mmol/L) was calculated. Partial correlation was conducted with adjustment for age, gender, education and HBP duration to assess the relationship between cognitive function (including details of cognitive function and global cognitive function) and LDL-C above/below the cut-off point. At LDL-C above 2.686 mmol/L, MoCA was associated with serum LDL-C. Moreover, increased LDL-C was found to be an independent risk factor of MCI in T2DM patients at this range by binary logistic regression. This finding is consistent with our previous work [13]. Xia et al.

Table 3: Binary logistic regression analysis for MCI risk in patients with different LDL-C levels

| P | LDL-C ≤ 2.686 mmol/l | LDL-C > 2.686 mmol/l |
|---|----------------------|----------------------|
| OR | 95%CL of OR | OR | 95%CL of OR |
| Lower | Higher | Lower | Higher |
| Age | 0.275 | 0.978 | 0.941 | 1.017 | 0.032* | 0.966 | 0.936 | 0.997 |
| Gender | 0.865 | 0.947 | 0.503 | 1.781 | 0.143 | 0.677 | 0.401 | 1.140 |
| Education | <0.001* | 1.232 | 1.113 | 1.363 | <0.001* | 1.214 | 1.119 | 1.316 |
| HBP Duration | 0.173 | 0.978 | 0.947 | 1.010 | 0.152 | 0.980 | 0.953 | 1.008 |
| LDL-C | 0.225 | 1.602 | 0.748 | 3.430 | 0.012* | 0.581 | 0.381 | 0.886 |

Abbreviations: LDL-C Low density lipoprotein cholesterol, MCI Mild cognitive impairment, HBP High blood pressure

*P < 0.05
suggested that uncontrolled cholesterol levels are associated with MCI in diabetic patients in a study with fMRI. Additionally, the brain damage of elevated cholesterol was found in our animal study [21]. These results partly confirm that hypercholesterolemia, especially elevated LDL-C is a risk factor of cognition decline and explain the conflict of previous studies in clarifying the relationship between cholesterol levels and cognitive function [41, 44–47].

Despite changes in Aβ metabolism and transformation in the brain, hypercholesterolemia tends to increase the risk of vascular dementia [48], while cholesterol deficiency may affect cognitive impairment by injuring the synaptic function [2]. Additional correlation analyses between neurological tests results and cholesterol levels were performed to further study the details of the damage of hypercholesterolemia to cognitive dysfunction. LDL-C level was positively associated with execution function in patients with hypercholesteremia. Similarly, our latest results show that hypercholesteremia, especially increased LDL-C may influence the executive function of patients with T2DM [49]. Additionally, Xia et al demonstrated the disordered functional connectivity of bilateral hippocampus-middle frontal gyrus in diabetic patients with poorly controlled LDL-C, and associated with executive function [13]. Although MoCA was not associated with LDL-C below 2.686 mmol/L in the present work, the association between visual space function and decrement of LDL-C was detected by partial correlation. Moreover, LDL-C (≤2.686 mmol/L) was positively associated with the visual space function, independent from age, gender, education, HBP duration and HbA1c in the multiple linear regression analysis. These results show that cholesterol should not be decreased to exceptionally low levels, especially for patients with risks of cognitive impairment.

Comparisons with other studies and what does the current work add to the existing knowledge

In this research, we investigated the relationship between cognitive function and LDL-C levels in different populations (with LDL-C above or below the cut-off point) with T2DM. Most previous studies indicated that elevated LDL-C levels is a risk or protective factors in specific individuals. Here, we found different levels of cognitive dysfunction in T2DM patients with different LDL-C levels. This novel findings provides an evidence for the management of LDL-C of T2DM patients, especially those with MCI.

Study strengths and limitations

In this work, we first demonstrated the inverted-U-shaped correlation between serum LDL-C level and cognitive functions among T2DM patients. Additionally, elevated LDL-C above the cut-off point is a risk factor of MCI. These results show that an appropriate level of LDL-C is beneficial for the cognitive function of T2DM patients. Since LDL-C was involved in this work, statins and other lipid-lowering drugs were recorded. However, names, dozes, and usage duration were not considered in subgroup analysis to avoid the decrease in the effectiveness of statistical results from limited numbers of participants. In this metabolite study, we only focused on the levels of cholesterol and medicine involved in cholesterol metabolism, but failed to investigate relationship between diet and cholesterol, which should be considered in the further research. Despite that elevated LDL-C is a risk factor of MCI in T2DM patients, and associated with executive function, the mechanism remains unclear and need further works, especially for the mechanisms involved in oxidized cholesterol. Additionally, unmatched patients were recruited in this cross-sectional study. Although these unmatched variables were adjusted, they may result in the small correlation. Finally, the present study only explained associations between different levels of LDL-C and cognitive function performance, but their causal relationship needs to be further clarified by cohort studies and basic experiments.

Table 4  Multiple linear regression analysis of the influence of LDL-C (>2.686 mmol/l) on TMTB

|                | P       | β       | 95% CL of β   |
|----------------|---------|---------|---------------|
|                |         | Lower of | Higher       |
| Age            | <0.001* | 2.878   | 1.980         | 3.777         |
| Gender         | 0.304   | 8.109   | −7.399        | 23.618        |
| Education      | <0.001* | −5.877  | −7.977        | −3.777        |
| HBP duration   | 0.108   | 0.683   | −0.151        | 1.516         |
| LDL-C          | 0.002*  | 19.393  | 7.051         | 31.735        |

**Lower Higher**

Abbreviations: LDL-C Low density lipoprotein cholesterol, TMTB Trail Making Test-B, AVLT-DR Auditory Verbal Learning test-delayed recall, HBP High blood pressure

*P < 0.05

Table 5  Multiple linear regression analysis of the influence of LDL-C (<2.686 mmol/l) on CDT

|                | P       | β       | 95% CL of β   |
|----------------|---------|---------|---------------|
|                |         | Lower of | Higher       |
| Age            | 0.219   | 0.009   | −0.006        | 0.025         |
| Gender         | 0.077   | −0.224  | −0.472        | 0.025         |
| Education      | 0.004*  | 0.051   | 0.016         | 0.086         |
| HBP duration   | 0.255   | −0.007  | −0.019        | 0.005         |
| LDL-C          | 0.033*  | 0.320   | 0.026         | 0.614         |

**Lower Higher**

Age, gender, education, HBP duration and LDL-C were entered as independent variables

Abbreviations: LDL-C Low density lipoprotein cholesterol, CDT Clock Drawing Test, HBP High blood pressure

*P < 0.05
**Conclusion**

To our best knowledge, this study is the first to report an inverted-U-shaped correlation between serum LDL-C and global cognitive function in T2DM patient. Appropriate cholesterol level, especially for LDL-C, is beneficial to maintaining normal cognitive function. Extremely high or low LDL-C levels are not desirable for cognitive function in T2DM patients. Additionally, excessive cholesterol levels damage the executive function, while deficient LDL-C impairs visual space function. Extremely high levels of LDL-C should be well controlled for the benefit of cognitive function in T2DM patients. Additionally, LDL-C should not be decreased to very low levels, especially for T2DM patients with cognition decline.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12944-021-01534-5.

**Additional information**

**Additional Table 1.** Association between MoCA and TC (or LDL-C).

**Additional Table 2.** Binary logistic regression analysis for MCI risk in all patients.

**Additional Table 3.** Comparison of line fitting and U-shaped curve fitting assessing the association between TC and MoCA.

**Additional Table 4.** Comparison of line fitting and U-shaped curve fitting assessing the association between LDL-C and MoCA.

**Supplementary Figure 1.** Comparison of linear and U curve association between TC and MoCA. Abbreviations: TC, Total cholesterol; MoCA, Montreal Cognitive Assessment.

**Acknowledgments**

Not applicable.

**Authors’ contributions**

SW and HZ designed the study, performed statistical analysis. WZ, TN, ZW, KA, WC, and JS performed the tests, collected the data and checked the statistical analysis. HZ wrote the manuscript draft. SW WZ, TN, ZW, KA, WC, and JS helped to revise the final version of paper. All authors have read and approved the final manuscript.

**Funding**

This work was partially supported by the National Natural Science Foundation of China (No.81570732, SW and No. 81370921, SW).

**Availability of data and materials**

The datasets analyzed in this study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

Every volunteer provided an informed consent before joining the research. The present work was approved by the Research Ethics Committee, Affiliated Zhongda Hospital of Southeast University (approval no. of ethics committee: 2013ZDSYLL0400).

**Consent for publication**

All participants provided consent for publication.

**Competing interests**

The authors declare that they have no competing interests.

**References**

1. Hussain G, Wang J, Rasul A, Anwar H, Imran A, Qasim M, et al. Role of cholesterol and sphingolipids in brain development and neurological diseases. Lipids Health Dis. 2019;18:26.
2. Mauch DG, Nagler K, Schumacher S, Gortz C, Muller EC, Otto A, et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science. 2001;294:1354–7.
3. Boisvert MM, Eriksson GA, Shokhirev MN, Allen NJ. The aging astrocyte Transcriptome from multiple regions of the mouse brain. Cell Rep. 2018;22:269–85.
4. Greeve I, Hermans-Borgmeyer I, Breiling S, Kasper D, Gomez-Isla T, Behl C, et al. The human DIMINUOTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer’s disease-associated neurodegeneration and oxidative stress. J Neurosci. 2000;20:7345–52.
5. Fukui K, Fens HA, Kahn CR. Effect of cholesterol reduction on receptor signaling in neurons. J Biol Chem. 2015;290:26383–92.
6. Papasotropoulos A, Lutjohann D, Bagli M, Locatelli S, Jessen F, Buschforth R, et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res. 2002;36:27–32.
7. Schonknecht P, Lutjohann D, Pantel J, Bardenheuer H, Hartmann T, von Bergmann K, et al. Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer’s disease compared to healthy controls. Neurosci Lett. 2002;324:83–5.
8. Leoni V, Caccia C. Oxysterols as biomarkers in neurodegenerative diseases. Chem Phys Lipids. 2011;164:515–24.
9. Popp J, Lewczuk P, Kolsch H, Meichsner S, Maier W, Kornhuber J, et al. Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer’s disease. J Neurochem. 2011;123:310–6.
10. Wang F, Xia JP. Correlation of cholesterol 24-hydroxylation and ATP-binding cassette transporter A1 polymorphisms with Alzheimer’s disease. Zhonghua Yi Xue Za Zhi. 2007;87:614–8.
11. Anstey KJ, Ashby-Mitchell K, Peters R. Updating the evidence on the association between serum cholesterol and risk of late-life dementia: review and Meta-analysis. J Alzheimers Dis. 2017;56:215–28.
12. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kiviven P, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease. Neuroepidemiology. 1998;17:14–20.
13. Xia W, Zhang B, Yang Y, Wang P, Yang Y, Wang S. Poorly controlled diabetes mellitus and cognition in T2DM patients: a restating-state fMRI study. Lipids Health Dis. 2015;14:47.
14. Mariani E, Monastero R, Mecocci P. Mild cognitive impairment: a systematic review. J Alzheimers Dis. 2007;12:23–35.
15. Bjorklund I, Meaney S. Brain cholesterol: long secret life behind a barrier. Antierosclor Thromb Vasc Biol. 2004;24:806–15.
16. Genaro-Mattos TC, Anderson A, Allen LB, Korade Z, Mirmics K. Cholesterol biosynthesis and uptake in developing neurons. ACS Chem Neurosci. 2019;10:13671–81.
17. van Deijk AF, Camargo N, Timmerman J, Heistek T, Brouwers JF, Mogavero F, et al. Astrocyte lipid metabolism is critical for synapse development and function in vivo. Glia. 2017;65:670–82.
18. Butterfield DA, Mattson MP. Apolipoprotein E and oxidative stress in brain with relevance to Alzheimer’s disease. Neurobiol Dis. 2020;138:104795.
19. Chiang YF. Bile acid metabolism and signaling. Compr Physiol. 2013;3:1191–212.
20. Pizzini A, Lunger L, Demetz E, Hilbe R, Weiss G, Ebenbichler C, et al. The role of 26S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res. 2002;36:27–32.
21. Wang SH, Huang Y, Yuan Y, Xia WQ, Wang P, Huang R. LDL receptor knock-out mice show impaired spatial cognition with hippocampal vulnerability to apoptosis and deficits in synapses. Lipids Health Dis. 2014;13:175.
22. Cai R, Han J, Sun J, Huang R, Tian S, Shen Y, et al. Effects of ABCA1 R219K polymorphism and serum lipid profiles on mild cognitive impairment in type 2 diabetes mellitus. Front Aging Neurosci. 2017;9:92.
23. Suzuki R, Lee K, Jing E, Biddinger SB, McDonald JG, Montine TJ, et al. Diabetes and insulin in regulation of brain cholesterol metabolism. Cell Metab. 2010;12:567–79.
24. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections.
for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.

25. Li Y, Teng D, Shi X, Qin G, Qin Y, Quan H, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020; 369:m997.

26. Koekkoek PS, Kappelle LJ, van den Berg E, Rutten GE, Biessels GJ. Cognitive function in patients with diabetes mellitus: guidance for daily care. Lancet Neurol. 2015;14:329–40.

27. McMillan JM, Mele BS, Hogan DB, Leung AA. Impact of pharmacological treatment of diabetes mellitus on dementia risk: systematic review and meta-analysis. BMJ Open Diabetes Res Care. 2018;6:e000563.

28. Dolan C, Glyn R, Lawlor B. A systematic review and Delphi study to ascertain common risk factors for type 2 diabetes mellitus and dementia and brain-related complications of diabetes in adults. Can J Diabetes. 2020; 44(7):628–35.

29. Portet F, Ouisset PJ, Visser PJ, Frisoni GB, Nobili F, Scheltens P, et al. Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI working Group of the European Consortium on Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2006;77:714–8.

30. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–9.

31. Leung JI, Lee GT, Lam YH, Chan RC, Wu JY. The use of the digit span test in screening for cognitive impairment in acute medical inpatients. Int Psychogeriatr. 2011;23:1569–74.

32. Chen YL, Chen YH, Lieh-Mak F. Semantic verbal fluency deficit as a familial trait marker in schizophrenia. Psychiatry Res. 2000;95:133–48.

33. Crowe SF. The differential contribution of mental tracking, cognitive flexibility, visual search, and motor speed to performance on parts a and B of the trail making test. J Clin Psychol. 1998;54:585–91.

34. Wang P, Huang R, Lu S, Xie W, Cai R, Sun H, et al. RAGE and AGEs in mild cognitive impairment of diabetic patients: a cross-sectional study. PLoS One. 2016;11:e0145521.

35. Tian S, Huang R, Han J, Cai R, Guo D, Lin H, et al. Increased plasma interleukin-1 beta level is associated with memory deficits in type 2 diabetic patients with mild cognitive impairment. Psychoneuroendocrinology. 2018;96:148–54.

36. Huang R, Tian S, Han J, Lin H, Guo D, Wang J, et al. U-shaped association between serum uric acid levels and cognitive functions in patients with type 2 diabetes: a cross-sectional study. J Alzheimers Dis. 2019;69:135–44.

37. Ma S, Li S, Lu R, Hou X, Nie S, Yin Q. Prevalence of mild cognitive impairment in type 2 diabetes mellitus is associated with serum galectin-3 level. J Diabetes Invest. 2020;11(5):1295–302.

38. Kivipelto M, Solomon A. Cholesterol as a risk factor for Alzheimer’s disease - epidemiological evidence. Acta Neurol Scand. 2006;114:50–7.

39. Chang CF, Liou YS, Lin TK, Ma S, Hu YR, Chen HY, et al. High exposure to statins decrease the risk of new-onset dementia a nationwide population-based longitudinal cohort study. Medicine. 2019;98:e16931.

40. Chu CS, Tseng PT, Stubbs B, Chen TY, Tang CH, Li DJ, et al. Use of statins and the risk of dementia and mild cognitive impairment: a systematic review and meta-analysis. Sci Rep. 2018;8:5804.

41. Lv YB, Yin ZX, Chei CL, Brasher MS, Zhang J, Kraus VB, et al. Serum cholesterol levels within the high Normal range are associated with better cognitive performance among Chinese elderly. J Nutr Health Aging. 2016;20:280–7.

42. Chui HC, Ramirez-Gomez L. Clinical and imaging features of mixed Alzheimer and vascular pathologies. Alzheimers Res Ther. 2015;7:21.

43. Li R, Wang T, Xie Q, Liu Y, Chen WH, Fan MY, et al. Effects of plasma lipids and statins on cognitive function. Chin Med J. 2018;131:471–6.

44. Solomon A, Karedal I, Ngandu T, Wolczyn B, Macdonald SW, Winblad B, et al. Serum total cholesterol, statins and cognition in non-demented elderly. Neurobiol Aging. 2009;30:1006–9.

45. Ma C, Yin Z, Zhu P, Luo J, Shi X, Gao X. Blood cholesterol in late-life and cognitive decline: a longitudinal study of the Chinese elderly. Mol Neurodegener. 2017;12:24.

46. Raffakin C, Qin H, Empara JP, Helmer C, Berr C, Tourou C, et al. Metabolic syndrome and risk for incident Alzheimer’s disease or vascular dementia: the Three-City study. Diabetes Care. 2009;32:169–74.

47. Mielke MM, Zandi PP, Sjogren M, Gustafson D, Ostling S, Steen B, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology. 2005;64:1689–95.

48. Jimenez-Conde J, Biffi A, Rahman R, Kanakis A, Butler C, Sonni S, et al. Hyperlipidemia and reduced white matter hyperintensity volume in patients with ischemic stroke. Stroke. 2010;41:437–42.

49. Zhang H, Huang R, Tian S, An K, Zhu W, Shi J, et al. The CC genotype of insulin-induced gene 2 rs7566065 is a protective factor of Hypercholesterolemia susceptible to mild cognitive impairment, especially to the executive function of patients with type 2 diabetes mellitus. Biomed Res Int. 2020;2020:4935831.